iShares Biotechnology ETF (NASDAQ:IBB) Shares Sold by Cerity Partners LLC

Cerity Partners LLC cut its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 5.7% during the 3rd quarter, Holdings Channel.com reports. The fund owned 50,213 shares of the financial services provider’s stock after selling 3,061 shares during the period. Cerity Partners LLC’s holdings in iShares Biotechnology ETF were worth $7,311,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of IBB. Darwin Wealth Management LLC purchased a new stake in iShares Biotechnology ETF during the third quarter valued at about $29,000. Highline Wealth Partners LLC purchased a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth about $30,000. Bbjs Financial Advisors LLC acquired a new stake in iShares Biotechnology ETF during the 2nd quarter worth approximately $31,000. Ashton Thomas Securities LLC purchased a new position in iShares Biotechnology ETF in the third quarter valued at approximately $36,000. Finally, Voisard Asset Management Group Inc. acquired a new position in iShares Biotechnology ETF during the third quarter valued at approximately $59,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

iShares Biotechnology ETF stock opened at $141.59 on Thursday. The firm has a fifty day moving average of $143.12 and a 200-day moving average of $141.97. iShares Biotechnology ETF has a 52-week low of $117.28 and a 52-week high of $150.57.

iShares Biotechnology ETF Announces Dividend

The business also recently declared a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were issued a $0.2005 dividend. The ex-dividend date was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.